肾移植患者不同免疫抑制方案对sCD30水平的影响

目的 观察肾移植患者术后不同免疫抑制方案对血清可溶性CD30(sCD30)水平的影响,并探讨其临床意义.方法 根据免疫抑制方案将肾移植患者分为环孢素(CsA)治疗组(79例)和他克莫司(FKS06)治疗组(33例),对患者临床资料、sCD30水平、肌酐值及血药浓度进行相关分析.结果 比较两组患者的临床资料、sCD30水平及第24月时肌酐值差异均无统计学意义(P>0.05);两组患者sCD30水平在手术后均逐渐下降,术后第7天开始较术前差异有统计学意义(P<0.05);线性回归分析提示,两组患者第24个月时肌酐值、血药浓度均与术前sCD30水平相关(P<0.05).结论 以CsA或FKS06为主的免疫抑制方案均能降低肾移植患者术后sCD30水平;并且sCD30水平与远期肾功能、血药浓度明显相关.

Association of sCD30 levels with immunosuppressive therapies after renal transplantation

Objective To analyze the relationship between sCD30 levels and immunosuppressive therapies after renal transplantation and find out its clinical application. Methods 112 patients who underwent all ograft kidney transplants were divided into cyclosporine A (CsA) and Tacrolimus (FK506) group according to their immunosuppressive regimes. Relevant clinical data including serum creatinine and drug concentration were collected for statistical analysis. Results There was no difference in posttranspant sCD30 levels between CsA and FK506 groups. Also, serum creatinine levels between two groups has no difference after long-term (24 months) immunosuppressive therapies (P>0.05). sCD30 level was decreased in both two groups, and there was statistically significant difference before and at the 7th day after surgery (P <0.05). There was a significant correlation between pretransplant sCD30 levels and serum creatinine levels at the 24th h post-transplant in the linear regression analysis (P<0.01 for both groups). The correlation between serum drug concentration and sCD30 level was also significant (P <0.05). Conclusion Both immunosuppressive regimes can reduce post-transplant sCD30 level. There is a correlation between sCD30 level with long-term renal function and serum drug concentration of CsA/FK506.